After initially setting out plans to lay off dozens of workers in Massachusetts, Replimune Group is now increasing those ...

FDA has now rejected Replimune’s melanoma immunotherapy RP1 on two separate occasions The drug was under consideration for use with Bristol Myers Squibb’s (BMY) Opdivo therapy Regulators maintained ...

The JavaScript innovation train is really picking up momentum lately, driven—as always—by the creativity of the JavaScript developer community. The emerging local-first SQL datastores crystalize ideas ...

Google has removed a whole section from its JavaScript SEO documentation because it was outdated and Google says loading content with JavaScript does not make it hard for Google Search. Google wrote ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...